Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease

Lilah M Besser1, Irene Litvan2, Sarah E Monsell1

  • 1National Alzheimer's Coordinating Center, University of Washington, 4311 11th Ave NE, Suite 300, Seattle, WA, 98105, USA.

Abstract

Insights

This study found that mild cognitive impairment due to Parkinson's disease (PD-MCI) is distinct from Alzheimer's Disease MCI (AD-MCI), with PD-MCI patients progressing more slowly to dementia.

Area of Science:

  • Neurology
  • Neuroscience
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) affects individuals with Parkinson's disease (PD-MCI) and Alzheimer's disease (AD-MCI).
  • Longitudinal comparisons between PD-MCI and AD-MCI are lacking.
  • Understanding differences is crucial for diagnosis and management.

Purpose of the Study:

  • To compare longitudinal characteristics of PD-MCI and AD-MCI.
  • To identify distinct clinical and cognitive trajectories.

Main Methods:

  • Utilized longitudinal data from the National Alzheimer's Coordinating Center's Uniform Data Set.
  • Compared 41 PD-MCI and 191 AD-MCI participants on demographics, APOE e4 status, clinical factors, and cognitive tests.
  • Employed multivariable linear regression with generalized estimating equations for analysis.

Main Results:

  • PD-MCI and AD-MCI groups differed significantly in demographics and clinical features.
  • Fewer PD-MCI participants progressed to dementia within one year compared to AD-MCI.
  • PD-MCI participants showed better baseline and longitudinal performance on cognitive tests, including memory, language, and processing speed, and on the CDR-SB.

Conclusions:

  • PD-MCI is clinically distinct from AD-MCI, necessitating tailored diagnostic and monitoring tools.
  • PD-MCI appears to have a slower conversion rate to dementia than AD-MCI.
  • Further research is needed to replicate these findings.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
672
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.6K